Therapeutic drug monitoring of tranexamic acid in plasma and urine of renally impaired patients using solid phase microextraction

IF 6.1 1区化学 Q1 CHEMISTRY, ANALYTICAL

Talanta Pub Date : 2021-04-01 DOI:10.1016/j.talanta.2020.121945

Nikita Looby , Tijana Vasiljevic , Nathaly Reyes-Garcés , Anna Roszkowska , Barbara Bojko , Marcin Wąsowicz , Angela Jerath , Janusz Pawliszyn

{"title":"Therapeutic drug monitoring of tranexamic acid in plasma and urine of renally impaired patients using solid phase microextraction","authors":"Nikita Looby , Tijana Vasiljevic , Nathaly Reyes-Garcés , Anna Roszkowska , Barbara Bojko , Marcin Wąsowicz , Angela Jerath , Janusz Pawliszyn","doi":"10.1016/j.talanta.2020.121945","DOIUrl":null,"url":null,"abstract":"<div><p>The purpose of the research was to develop an improved solid phase microextraction<span><span><span> (SPME)-based sampling protocol for the therapeutic drug monitoring of tranexamic acid (TXA) from plasma and urine of patients with chronic renal dysfunction (CRD) in order to correct the current dosing schedule to accommodate these patients. A 12-fold improvement in sampling efficiency (25 min for 96 samples -22 s per sample) was achieved with the use of hydrophilic-lipophilic balance (HLB)-coated SPME devices, thereby enabling high throughput profiling of TXA in the plasma and urine of 49 CRD patients undergoing cardiac surgery. A limit of quantification of 10 μg/mL and 25 μg/mL was obtained for plasma and urine respectively while a method accuracy of 103–105% and a precision of less than 8% was achieved. The results from this study were ultimately used by clinicians at the Toronto General Hospital to design a corrective </span>pharmacokinetic dosing schedule for CRD patients. This green method further presents potential application in the clinical field for the fast high throughput monitoring of TXA not only in plasma but also in urine – a biological matrix seldom explored for the analysis of TXA – without the need for solvent-assisted extraction, extensive sample pre-treatment or clean-up, </span>derivatization or excessive pH adjustment to improve amenability for analytical separation.</span></p></div>","PeriodicalId":435,"journal":{"name":"Talanta","volume":"225 ","pages":"Article 121945"},"PeriodicalIF":6.1000,"publicationDate":"2021-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.talanta.2020.121945","citationCount":"11","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Talanta","FirstCategoryId":"92","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0039914020312364","RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, ANALYTICAL","Score":null,"Total":0}

引用次数: 11

Abstract

The purpose of the research was to develop an improved solid phase microextraction (SPME)-based sampling protocol for the therapeutic drug monitoring of tranexamic acid (TXA) from plasma and urine of patients with chronic renal dysfunction (CRD) in order to correct the current dosing schedule to accommodate these patients. A 12-fold improvement in sampling efficiency (25 min for 96 samples -22 s per sample) was achieved with the use of hydrophilic-lipophilic balance (HLB)-coated SPME devices, thereby enabling high throughput profiling of TXA in the plasma and urine of 49 CRD patients undergoing cardiac surgery. A limit of quantification of 10 μg/mL and 25 μg/mL was obtained for plasma and urine respectively while a method accuracy of 103–105% and a precision of less than 8% was achieved. The results from this study were ultimately used by clinicians at the Toronto General Hospital to design a corrective pharmacokinetic dosing schedule for CRD patients. This green method further presents potential application in the clinical field for the fast high throughput monitoring of TXA not only in plasma but also in urine – a biological matrix seldom explored for the analysis of TXA – without the need for solvent-assisted extraction, extensive sample pre-treatment or clean-up, derivatization or excessive pH adjustment to improve amenability for analytical separation.

Abstract Image

查看原文本刊更多论文

固相微萃取法监测肾损害患者血浆和尿液中的氨甲环酸

本研究的目的是开发一种改进的基于固相微萃取(SPME)的采样方案，用于慢性肾功能不全(CRD)患者血浆和尿液中的氨甲环酸(TXA)的治疗药物监测，以纠正当前的给药计划，以适应这些患者。使用亲水-亲脂平衡(HLB)涂层的SPME装置，采样效率提高了12倍(96个样品25分钟-每个样品22秒)，从而实现了49例接受心脏手术的CRD患者血浆和尿液中TXA的高通量分析。血浆和尿液的定量限分别为10 μg/mL和25 μg/mL，方法准确度为103 ~ 105%，精密度小于8%。这项研究的结果最终被多伦多总医院的临床医生用于为CRD患者设计纠正药代动力学给药方案。这种绿色的方法在临床领域有潜在的应用前景，不仅可以用于血浆中，也可以用于尿液中TXA的快速高通量监测，而不需要溶剂辅助提取，大量的样品预处理或清理，衍生化或过度的pH调整，以提高分析分离的适应性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Talanta 化学-分析化学

CiteScore

12.30

自引率

4.90%

发文量

861

审稿时长

29 days

期刊介绍： Talanta provides a forum for the publication of original research papers, short communications, and critical reviews in all branches of pure and applied analytical chemistry. Papers are evaluated based on established guidelines, including the fundamental nature of the study, scientific novelty, substantial improvement or advantage over existing technology or methods, and demonstrated analytical applicability. Original research papers on fundamental studies, and on novel sensor and instrumentation developments, are encouraged. Novel or improved applications in areas such as clinical and biological chemistry, environmental analysis, geochemistry, materials science and engineering, and analytical platforms for omics development are welcome. Analytical performance of methods should be determined, including interference and matrix effects, and methods should be validated by comparison with a standard method, or analysis of a certified reference material. Simple spiking recoveries may not be sufficient. The developed method should especially comprise information on selectivity, sensitivity, detection limits, accuracy, and reliability. However, applying official validation or robustness studies to a routine method or technique does not necessarily constitute novelty. Proper statistical treatment of the data should be provided. Relevant literature should be cited, including related publications by the authors, and authors should discuss how their proposed methodology compares with previously reported methods.